Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
103.8 USD -0.07% Intraday chart for Moderna, Inc. -7.00% +4.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing MT
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo
Market outlook is uncertain, but optimism prevails Our Logo
Redburn Adjusts Moderna's Price Target to $117 From $110 MT
Moderna pauses Kenya plant plans as COVID vaccine demand wanes RE
Moderna Pausing Plan to Build Kenya Vaccine Production Plant MT
Moderna Reportedly Pausing Plan to Build Kenya Vaccine Production Plant MT
Moderna Reportedly Putting Plan for Kenya Vaccine Plant on Hold MT
Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps RE
Health Care Down on Retreat From Risk -- Health Care Roundup DJ
U.S. stocks inch mostly higher ahead of CPI data RE
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup DJ
Equities Mostly Rise With Upcoming Inflation Data, Fed Minutes in Focus MT
Equities Close Mostly Higher With Upcoming CPI Data, Fed Minutes in Focus MT
S&P 500 ends slightly higher as markets brace for inflation data, earnings RE
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Wall St backs down as markets brace for inflation data, earnings RE
Equities Fall Intraday as Markets Await Wednesday's CPI, Fed Minutes MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Sector Update: Health Care MT
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study MT
Moderna jumps as personalized cancer vaccine shows benefit in early study RE
MODERNA : Jefferies confirms its Buy recommendation CF
Geneos cancer vaccine shrinks liver tumors in small trial RE
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
103.9 USD
Average target price
134.3 USD
Spread / Average Target
+29.31%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Sector Update: Health Care Stocks Catching Up with Other Sectors